My feeling is that OncoCyte's cancer diagnostic products will make some waves. Out by late 2017, perfect timing as cancer diagnostic/treatment will within five years be totally treatable.
Big pharma will snap OncoCyte for no less then 400 MIL. Make no mistake cancer is big business and BTX is ahead of the curve with industry leading ip 5+ years in the making.
After the buyout BTX's huge profits will then move heart regen and cancer therapies into clinical trials and within 5 years become a must have biotech stock.
Biotime did aggressively persue hESC ip, but it's not like they were greedy about it, NOBODY else 5-10 years ago would touch it. Now things are starting to change and Ithink West had guts to chance it and now partners are lining up to host their clinical trials.
This proves that the future of the use of stem cells within the medical industry is NOT just either embryonic or adult(skin). Take for instance autogolous stem cell transfusions, these are safe and proven and used for decades . Stem cell transfusions use PROGENITOR stem cells.
BTW, BTX also has extensive ip on stem cell growth factors which will also be an avenue along with 'off the shelf' progenitors.
Now that its clear cable companies have lost and internet/phone service providers have won AT&T will dominate. Take a look and see T's maximum chart. $60 range in the early 1090's when economy hit bottom.
Good chance within the next five years T shares will pop as economy stumbles. Netflix, Hulu, Amazon and content providers will take a hit while T phone users will grow.
Cancer market is huge, OCX will be one of the first with nano/big-data cancer diagnostic products available this year. Should be very lucrative.
My take is that BTX will sell OCX after they reap profits over the course of 2016. If so the buyot would likely occur just before the release the 2.0 version of PanC. OCX will at that point be $12-20 and the buyout will fetch a share price of $25-$30.
Another subsidiary to ipo by years end, BTX one of the best next-gen biotech investments for 2016.